Alto Neuroscience
News
William Blair Reiterates "Outperform" Rating for Alto Neuroscience (NYSE:ANRO)
Ticker Report Alto Neuroscience (NYSE:ANRO - Get Free Report)s stock had its "outperform" rating restated by equities researchers at William Blair in a research note issued on Tuesday, RTT News reports...\n more…
Alto Neuroscience (NYSE:ANRO) Given Outperform Rating at Wedbush
Ticker Report Wedbush reiterated their outperform rating on shares of Alto Neuroscience (NYSE:ANRO - Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. Wedbush currently has...\n more…
Research Analysts Offer Predictions for Alto Neuroscience, Inc.'s Q3 2024 Earnings (NYSE:ANRO)
Ticker Report Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Analysts at Wedbush issued their Q3 2024 EPS estimates for shares of Alto Neuroscience in a research report issued to clients and investors on...\n more…
Alto Neuroscience (NYSE:ANRO) Now Covered by Wedbush
Ticker Report Investment analysts at Wedbush started coverage on shares of Alto Neuroscience (NYSE:ANRO - Get Free Report) in a report issued on Tuesday, MarketBeat Ratings reports. The firm set an "outperform...\n more…
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Ant
Business Wire Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a...\n more…
Alto Neuroscience to Participate in Upcoming Investor Conferences
Business Wire Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...\n more…